Prognostic significance of VEGF, bcl2 and survivin expression in advanced non-small cell lung cancer

[M. Z. Marković]

118 listova

Karcinom pluća je jedan od vodećih uzroka smrti u svetu. Pretpostavka modernog doba istraživanja je da se ishod pacijenata sa ovom dijagnozom, može poboljšati kombinovanjem kliničkih parametara sa različitim biološkim markerima. Cilj ovog istraživanja je ispitivanje korelacije ekspresije VEGF, Bcl2 i survivina u nemikrocelularnom karcinomu pluća sa patohistološkim parametrima tumora i kliničkim parametrima ispitivanih bolesnika. U istraživanje su uključeni pacijenti koji su imali nesitnoćelijski karcinom pluća, a koji su na osnovu kliničkog stadijuma klasifikovani u lokalno uznapredovali i metastatski klinički stadijum. Pored dijagnoze, mikroskopski pregled je uključivao određivanje standardnih i nestandardnih osobina tumora. Histopatološki izveštaj sadrži podatke o histološkom tipu i stepenu diferencijacije tumora, nuklearnom gradusu i prisustvu stromalne mononuklearne reakcije. Imunohistohemijski, određivana je tkivna ekspresija relevantnih markera, primenom antitela (VEGF, Bcl2 i survivin). U ispitivanoj populaciji je pokazano je da histološke podgrupe nesitnoćelijskog karcinoma pluća pokazuju razliku u VEGF i Bcl-2 ekspresiji. Kada je posmatran celokupan uzorak ispitanika, pokazan je uticaj VEGF ekspresije na preživljavanje kod pacijenata u IV stadijumu bolesti. Takođe, pokazana je povezanost VEGF ekspresije i primene antiangiogeneznog agensa kod adenokarcinoma. Ekspresija VEGF bila je u negativnoj korelaciji sa Bcl-2 kod pacijenata sa nesitnoćelijskim karcinomom pluća. Sa druge strane, survivin nije pokazao statističku značajnost u odnosu na ispitivane kliničkopatološke karakteristike pacijenata sa nesitnoćlijskim karcinom pluća. Ispitivani markeri imaju značajnu ulogu u terapijskom odgovoru i kliničkom ishodu kod pacijenata sa nesitnoćelijskim karcinomom pluća.

Lung cancer is the most common cause of mortality from malignant tumors worldwide.The assumption of the modern era of research is that the outcome of patients with this diagnosis can be improved by combining clinical parameters with various biological markers. The aim of this research was to evaluate the relationship between VEGF, Bcl2 and survivin expression, clinicopathological features and survival in patients with advanced nonsmall cell carcinoma. The study included patients who had non-small cell lung carcinoma, and who were classified as locally advanced and metastatic clinical stage based on the clinical stage. In addition to diagnostics, the microscopic examination included the determination of standard and non-standard features of the tumor. The histopathological report contains data on the histological type and degree of differentiation of the tumor, the nuclear grade and the presence of a stromal mononuclear reaction. Immunohistochemically, tissue expression of relevant markers was determined using antibodies (VEGF, Bcl2 and survivin). In the studied population, it was shown that histological groups of non-small cell carcinoma show a difference in VEGF and Bcl-2 expression. When the entire sample of subjects was observed, it showed the influence of VEGF expression on survival in patients in stage IV of the disease. Also, the association between VEGF expression and the use of an antiangiogenic agent in adenocarcinoma was shown. VEGF expression was negatively correlated with Bcl-2 in patients with non-small cell lung cancer. On the other hand, survivin did not show statistical significance in relation to the examination of clinicopathological characteristics of patients with lung cancer. The investigated markers have a significant role in the therapeutic response and clinical outcome in patients with non-small cell lung cancer.

nemikrocelularni karcinom pluća, VEGF, Bcl2, survivin

non-small cell lung carcinoma (NSCLC); bcl-2; VEGF, survivin

616.24‑006.6-036:616-097(043.3)

Pluća - Karcinom - Imunohistohemijska ispitivanja

Tekst